-
Mashup Score: 0
Patients with advanced endometrial cancer experience early responses to lenvatinib plus pembrolizumab in both patients who were mismatch repair proficient and all-comers.
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Early responses were shown with to lenvatinib plus pembrolizumab in the mismatch repair proficient and all-comer populations of patients with advanced endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Researchers randomly assigned patients with RCC to receive 18 mg or 14 mg of lenvatinib plus 5 mg everolimus to determine which produced better HRQOL.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Robert Coleman, MD, discussed dosing of lenvatinib plus pembrolizumab in patients with endometrial carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0KEYNOTE-775: Lenvatinib/Pembrolizumab in Patients with Advanced Endometrial Carcinoma - 1 year(s) ago
Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
#Lenvatinib & #pembrolizumab Combo Yields Robust, Enduring Responses in #endometrialcancer. From @CancerNetwrk #gyncsm #SGOMtg @Lenvima_HCP @KEYTRUDA #SGO2023 #clinicaltrial #KEYNOTE https://t.co/mT3fpHEIBp